Stock Screener App

무료 -

설치하다

0.5061

2.68% -0.0139

Pasithea Therapeutics Corp (KTTA)

개요 뉴스 가격 이력 Financials 토론 예측

Pasithea Therapeutics Corp 주식(KTTA)의 최신 뉴스

Coastlands holds 3.84M shares in Pasithea Therapeutics (KTTA) — 11.48% disclosed - Stock Titan

Pasithea Therapeutics Corp Warrant 2021-12.08.26 on Pasithea Therapeutics Financial Disclosures & SEC Filings - TradingView

Pasithea extends dose escalation for MEK inhibitor PAS-004 - Investing.com UK

Pasithea extends dose escalation for MEK inhibitor PAS-004 By Investing.com - Investing.com South Africa

Pasithea Therapeutics Corp. announced that its candidate drug Pas-4 demonstrated a favorable safety profile in clinical studies. - Bitget

Pasithea reports positive PAS-004 Phase 1 cancer data - grafa.com

Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion - Investing News Network

Pasithea says PAS-004 stayed tolerable in cancer patients as dosing widens - Stock Titan

symbol__ Stock Quote Price and Forecast - CNN

Enterprise value to revenue forward of Pasithea Therapeutics Corp. – NASDAQ:KTTA - TradingView

Price to book forward of Pasithea Therapeutics Corp. – NASDAQ:KTTA - TradingView

Pasithea Therapeutics Company Profile & Introduction - Moomoo

Enterprise value to revenue forward of Pasithea Therapeutics Corp. – BOATS:KTTAW - TradingView

Price to earnings forward of Pasithea Therapeutics Corp. – BOATS:KTTAW - TradingView

Price to sales forward of Pasithea Therapeutics Corp. – BOATS:KTTAW - TradingView

Pasithea Therapeutics Corp. Actuals & Estimates (NASDAQ:KTTA) - TradingView

KTTA Forecast — Price Target — Prediction for 2027 - TradingView

Pasithea Therapeutics Corp. Financial Disclosures & SEC Filings - TradingView

Form 13G Pasithea Therapeutics Corp. For: 23 June By Investing.com - Investing.com South Africa

Stonepine Group reports 5.8% stake in Pasithea Therapeutics (KTTA) - Stock Titan

Major Investor Quietly Boosts Stake in Pasithea Therapeutics - TipRanks

Coastlands Capital LP acquires $53,000 of Pasithea stock - Investing.com UK

Coastlands Capital LP acquires $53,000 of Pasithea stock By Investing.com - Investing.com Australia

Form 4 Pasithea Therapeutics Corp For: 22 June By Investing.com - Investing.com Nigeria

Coastlands Capital LP (KTTA) adds 100,000 Pasithea Therapeutics shares in open-market buy - Stock Titan

Pasithea Therapeutics Corp (KTTA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Pasithea Therapeutics Corp (KTTA) Valuation: PE, PB & Fair Value Analysis - TradingKey

Pasithea Therapeutics Corp (KTTA) Institutional Confidence - TradingKey

Pasithea Therapeutics Corp (KTTA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Pasithea Therapeutics Corp (KTTA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Pasithea Therapeutics Corp (KTTA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Pasithea Therapeutics Corp (KTTA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Pasithea Therapeutics Corp (KTTA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Pasithea Therapeutics Corp (KTTAW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Pasithea Therapeutics Corp (KTTAW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Pasithea Therapeutics Corp (KTTAW) Valuation: PE, PB & Fair Value Analysis - TradingKey

Pasithea Therapeutics Corp (KTTAW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Pasithea Therapeutics Corp (KTTAW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Pasithea Therapeutics Corp (KTTAW) Institutional Confidence - TradingKey

Pasithea Therapeutics Corp (KTTAW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Analysts Are Bullish on Top Healthcare Stocks: Pasithea Therapeutics Corp (KTTA), Adaptive Biotechnologies (ADPT) - The Globe and Mail

Pasithea Therapeutics Corp (KTTAW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Pasithea Therapeutics Corp - TradingKey

Pasithea Therapeutics Corp (KTTA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

KTTA Reiterates by HC Wainwright & Co. -- Price Target Maintained at $3.00 - GuruFocus

Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial - Investing News Network

Pasithea amends phase 1/1b trial protocol for PAS-004 in NF1 - Investing.com UK

Pasithea Therapeuticson Track to Release I - Moomoo

Pasithea expands PAS-004 clinical trial protocol - grafa.com

Pasithea Therapeutics Announces Exhibit at Children's Tumor Foundation 2026 NF Conference - Investing News Network

Pasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF Conference - The Manila Times

Pasithea Therapeutics (KTTA) could find a support soon, here's why you should buy the stock now - MSN

Pasithea Therapeutics Corp. (KTTA) Q1 2026 Earnings: Narrower-than-Expected Loss Lifts SharesEPS Consistency Score - newsline.com

INSM

$113.07

1.38%

ROIV

$35.27

0.23%

RPRX

$57.70

1.38%

MRNA

$78.94

3.59%

ONC

$305.62

1.15%

RVMD

$190.47

0.31%

야후에서 열기 | 구글에서 열기 | 핀비즈에서 열기 | MarketWatch에서 열기 | EDGAR에서 열기 | 로이터에서 공개